

Letter To The Editor

Does NDUFS3-Mediated Cell Death Contribute To the Phenotype of NDUFS3 Mutations C.418C>T and C.595C>T?

Josef Finsterer, MD, PhD.¹, Sinda Zarrouk-Mahjoub, PhD.²

¹Krankenanstalt Rudolfstiftung, Messerli Institute, Veterinary University of Vienna, Vienna, Austria

²University of Tunis El Manar and Genomics Platform, Pasteur Institute of Tunis, Tunisia. Austria

*Corresponding Author

Finsterer J, MD, PhD

Keywords: Mitochondrial, mtDNA, phenotype, genotype, epilepsy, seizures, CNV, NDUFS3 gene.

With interest we read the article by Lou *et al.*, (2018) about a male in whom Leigh syndrome (LS) was diagnosed at age 7 months and who died at age 2 years. He manifested clinically with lactic acidosis, torticollis, leucoencephalopathy, and T2-hyperintensities in the basal ganglia and brainstem (Lou, X., *et al.*, 2018). The genetic cause of LS was the complex heterozygous mutations c.418C>T and c.595C>T in the *NDUFS3* gene (Lou, X., *et al.*, 2018). Follow-up MRI at age 1 year showed progression of the cerebral lesions (Lou, X., *et al.*, 2018). We have the following comments and concerns.

The description of the phenotype is thrifty. It would be helpful for establishing genotype phenotype correlations to exactly know which phenotypic manifestations were present at diagnosis and which developed over the course. Patients with LS not only manifest in the brain but also in other organs, such as the eyes, ears, endocrine organs, heart, or gastrointestinal tract (Sofou, K. *et al.*, 2018). In the muscle patients with LS may manifest as ophthalmoplegia, myopathy of the limb muscles, or scoliosis (Sofou, K. *et al.*, 2018; Benit, P. *et al.*, 2004). In the eyes optic atrophy may be found (Benit, P. *et al.*, 2004). Otologic manifestations include hypoacusis. In the brain LS may additionally manifest with ataxia, spasticity, failure to thrive, generalised hypotonia, nystagmus, dysphagia, central hypoventilation, dyskinesia, axial dystonia, or epilepsy (Sofou, K. *et al.*, 2018; Benit, P. *et al.*, 2004). In the heart LS manifests with cardiomyopathy or arrhythmias (Ogawa, E. *et al.*, 2017). Gastrointestinal manifestations include hepatopathy with liver failure, pancreatitis, or intestinal

pseudo-obstruction (Benit, P. *et al.*, 2004; Itai, T. *et al.*, 2018). Which of these manifestations were found in the index case?

The index patient carried two mutations in the *NDUFS3* gene and both were regarded as pathogenic (Lou, X., *et al.*, 2018). Since the father carried the mutation c.418C>T and the mother the mutation c.595C>T, it is conceivable that both of them manifested clinically. Which were the clinical manifestations in the parents of the index case? Did the mother also manifest with LS since the mutation c.595C>T has been previously reported in association with LS (Benit, P. *et al.*, 2004). Was severity of clinical manifestation similar or dissimilar in both parents and between the index case and parents? Were also other first-degree relatives investigated?

Cleavage of *NDUFS3* by granzyme-A represents a novel pathway of programmed cell death (Lieberman, J. 2010). Cleavage of *NDUFS3* disrupts the mitochondrial metabolism and generates reactive oxygen species (ROS) which drive the endoplasmic reticulum-associated SET complex into the nucleus, where it activates single-stranded DNA damage (Lieberman, J. 2010). Cells that are resistant to the caspases or GzmB by overexpressing bcl-2 family anti-apoptotic proteins or caspase or GzmB protease inhibitors, are sensitive to GzmA (Lieberman, J. 2010). Did affection of this pathway contribute to the pathogenicity of the two mutations?

Quick Response Code



Journal homepage:

<http://www.easpublisher.com/easims/>

Article History

Received: 18.02.2019

Accepted: 27.02.2019

Published: 14.03.2019

Copyright @ 2019: This is an open-access article distributed under the terms of the Creative Commons Attribution license which permits unrestricted use, distribution, and reproduction in any medium for non commercial use (NonCommercial, or CC-BY-NC) provided the original author and source are credited.

To summarise, this interesting case could be more meaningful if the phenotype of the index case and of his parents would have been described in detail and if the influence of the mutations on the function of NDUFS3 in the novel pathway of programmed cell death would have been discussed.

REFERENCES

1. Lou, X., Shi, H., Wen, S., Li, Y., Wei, X., Xie, J., ... & Lyu, J. (2018). A Novel NDUFS3 mutation in a Chinese patient with severe Leigh syndrome. *Journal of human genetics*, 63(12), 1269.
2. Sofou, K., de Coo, I. F., Ostergaard, E., Isohanni, P., Naess, K., De Meirleir, L., ... & Tulinius, M. (2018). Phenotype-genotype correlations in Leigh syndrome: new insights from a multicentre study of 96 patients. *Journal of medical genetics*, 55(1), 21-27.
3. Benit, P., Slama, A., Cartault, F., Giurgea, I., Chretien, D., Lebon, S., ... & Rustin, P. (2004). Mutant NDUFS3 subunit of mitochondrial complex I causes Leigh syndrome. *Journal of medical genetics*, 41(1), 14-17.
4. Ogawa, E., Shimura, M., Fushimi, T., Tajika, M., Ichimoto, K., Matsunaga, A., ... & Mori, M. (2017). Clinical validity of biochemical and molecular analysis in diagnosing Leigh syndrome: a study of 106 Japanese patients. *Journal of Inherited Metabolic Disease: Official Journal of the Society for the Study of Inborn Errors of Metabolism*, 40(5), 685-693.
5. Itai, T., Ishikawa, H., Kurosawa, K., & Tsuyusaki, Y. (2018). A case of prenatal chronic intestinal pseudo-obstruction associated with Leigh syndrome. *Clinical case reports*, 6(8), 1474.
6. Lieberman, J. (2010). Granzyme A activates another way to die. *Immunological reviews*, 235(1), 93-104.